达安基因：一年亏了8个亿！

Core Viewpoint - The company DaAn Gene announced an expected net profit attributable to shareholders for 2025 to be between -865 million yuan and -607 million yuan, compared to -925 million yuan in the same period last year, indicating a slight improvement in losses [1][4]. Financial Summary - The projected net profit attributable to shareholders for 2025 is between -865 million yuan and -607 million yuan, while the previous year's figure was -925 million yuan [2][5]. - The net profit after deducting non-recurring gains and losses is expected to be between -938 million yuan and -658 million yuan, compared to -823 million yuan in the same period last year [2][5]. - Basic earnings per share are projected to be between -0.62 yuan and -0.43 yuan, compared to -0.66 yuan in the previous year [2][5]. - For the first three quarters of 2025, the company reported revenue of 504 million yuan and a net profit attributable to shareholders of -142 million yuan, with a significant decline expected in the fourth quarter [2][5]. Reasons for Performance Changes - The decrease in operating revenue is attributed to market demand, the implementation of centralized procurement policies, and an increase in the VAT rate on self-produced reagent products to 13%. Despite efforts to enhance operational efficiency, fixed costs have led to a negative impact on gross profit, resulting in operational losses for the year [3][6]. - The performance of joint ventures improved compared to the previous year, leading to an increase in investment income recognized by the company, which positively affected the net profit attributable to shareholders [3][6]. - The company has strengthened the collection of historical accounts receivable, resulting in a decrease in the provision for credit impairment losses compared to the previous year. However, the company also conducted a comprehensive review of various assets and recognized impairment losses on assets showing signs of impairment, which increased compared to the previous year [3][6]. - The fair value of other non-current financial assets increased, contributing to a rise in net profit attributable to shareholders, with this non-recurring gain before tax increasing by approximately 180 million yuan compared to the previous year [3][6].